InflaRx schedules November 3 results and values InflaRx stock at USD 232.1 million

Published on 10/27/2026 at 12:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Izicopan cut kidney injury markers in two models on October 22, 2026. InflaRx stock costs EUR 1.41 on October 27, 2026, with a USD 232.1 million market value.

Events and clinical evidence

InflaRx scheduled third-quarter results for November 3, 2026.
Izicopan reduced kidney injury markers at a 100 mg/kg dose, with both creatinine and blood urea nitrogen results at p < 0.001 on October 22, 2026.
InflaRx stock trades at EUR 1.41 at 12:50 p.m. CET at Lang & Schwarz on October 27, 2026.
InflaRx had a USD 232.1 million market capitalization as of October 26, 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx N.V. (NL0012661870) scheduled its third-quarter 2026 results for November 3, 2026, while its market capitalization stood at USD 232.1 million as of October 26, 2026. The company also set investor meetings and conference appearances for November, according to GlobeNewswire on October 27, 2026.

November brings several milestones

The November 3 release will arrive before the market opens through a Form 6-K, followed by a virtual Capital Markets Day from 2:00 p.m. to 3:00 p.m. CET. The event is intended to outline InflaRx's development strategy for izicopan in ANCA-associated vasculitis and additional renal diseases, as GlobeNewswire reported.

What does the kidney data show?

InflaRx's October 22, 2026 release described two hamster kidney-injury models for izicopan. A single oral dose of 100 mg/kg reduced creatinine and blood urea nitrogen in the ischemia-reperfusion model, with p < 0.001 for both measures, while a 14-day regimen improved blood urea nitrogen and tissue-injury scores in the obstruction model, according to InflaRx.

Three dated steps shape the pipeline

On October 1, 2026, InflaRx appointed Gabriela Alperovich as senior vice president and global head of clinical development, bringing more than 20 years of industry experience, according to InflaRx. On October 22, 2026, the company presented izicopan data from two kidney models, including the 100 mg/kg dose and 14-day regimen. On October 27, 2026, it scheduled third-quarter results and a Capital Markets Day for November 3, 2026.

Dates that matter next

InflaRx is due to publish third-quarter 2026 financial and operating results on November 3, 2026. Its virtual Capital Markets Day is scheduled for the same date, while the Guggenheim Securities Healthcare Innovation Conference runs from November 9 to November 11, 2026, according to GlobeNewswire.

Stock price and valuation

InflaRx is a clinical-stage biotechnology company developing complement-system inhibitors, with izicopan as its lead oral program. Its primary listing is Nasdaq under ticker IFRX, and the stock's 52-week range was USD 0.80 to USD 2.95 as of October 26, 2026. The stock was trading at EUR 1.41 at Lang & Schwarz on October 27, 2026 at 12:50 p.m. CET.

The further course of trading is shown by the continuously updated real-time quote of InflaRx stock.